Product Description
Durlobactam (DUR; also known as ETX2514) is a novel _-lactamase inhibitor with broad activity against Ambler class A, C, and D _-lactamases. (Sourced from: https://journals.asm.org/doi/10.1128/AAC.00071-20)
Mechanisms of Action: LACTB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innoviva
Company Location: BURLINGAME CA 94010
Company CEO: Pavel Raifeld
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acinetobacter Infections|Pneumonia, Ventilator-Associated|Pneumonia, Bacterial|Bacteremia
Phase 2: Pyelonephritis|Communicable Diseases|Urinary Tract Infections
Phase 1: Acinetobacter Infections|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20191712 |
CTR20191712 | P1 |
Completed |
Healthy Volunteers |
2020-08-26 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT04018950 |
CS2514-2018-0002 | P1 |
Completed |
Acinetobacter Infections |
2019-07-26 |
50% |
2019-09-04 |
Primary Endpoints|Treatments|Trial Status |
NCT03985410 |
CS2514-2018-0003 | P1 |
Completed |
Acinetobacter Infections |
2019-07-24 |
12% |
2025-08-27 |
Primary Endpoints|Treatments |
NCT03303924 |
CS2514-2017-0001 | P1 |
Completed |
Healthy Volunteers |
2017-10-17 |
2019-03-21 |
Treatments |
|
NCT02971423 |
CS2514-2016-0001 | P1 |
Completed |
Acinetobacter Infections |
2017-06-01 |
2019-03-21 |
Treatments |
|
ACTRN12616000995471 |
ACTRN12616000995471 | P1 |
Completed |
Acinetobacter Infections |
2017-05-04 |
2024-08-29 |
Treatments |
|
NCT03445195 |
CS2514-2017-0003 | P2 |
Completed |
Urinary Tract Infections|Pyelonephritis|Communicable Diseases |
2018-05-17 |
33% |
2019-03-22 |
Treatments |
2017-002608-29 |
2017-002608-29 | P2 |
Completed |
Urinary Tract Infections|Pyelonephritis |
2018-05-17 |
2022-03-13 |
Treatments |
|
NCT03894046 |
ATTACK | P3 |
Completed |
Bacteremia|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Acinetobacter Infections |
2021-07-26 |
21% |
2023-02-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2018-002526-23 |
2018-002526-23 | P3 |
Completed |
Acinetobacter Infections |
2021-07-26 |
2025-05-06 |
Treatments |